Past timeline from RMZport:
Quote:rmzport Member Level Monday, 06/19/17 06:27:48 AM
Re: DesireToLearn post# 186328
Post # of 186429
Partial list. Dates correspond to Co press releases.
K= kevetrin B= brilacidin P= prurisol
CTIX Clinicals, FDA, Milestones
10/5/12 K Ph1 starts
1/24/13 K renal, in vivo combo w/sunitinib, first ever tumor shrinkage witnessed
6/26/13 K MD Anderson, Multiple Myeloma and Lymphoma
9/9/13 Acquired PolyMedix assets
2/25/14 B/ABSSSI Ph2b trial commences
3/24/14 P Ph1 crossover study starts
6/23/14 B Candida, Fox Chase Med collab/SBIR $1.5 mil Grant
8/7/14 B/ABSSSI meets Ph2b endpoints
10/13/14 B/Oral Mucositis (OM) Ph2 trial to commence
12/10/14 B/ABSSSI granted FDA QIDP designation
12/10/14 P Ph2 start approved by FDA
5/22/15 K Ph1 allowed additional patient enrollment
7/20/15 K granted OrphanDrug Designation for Ovarian cancer
8/6/15 P Ph2 commences
11/23/15 K granted FDA OrphanDrug Designation for Retinoblastoma (eye cancer)
11/25/15 B/OM granted FDA Fast Track Designation
12/1/15 K granted FDA "Rare Pediatric Disease Designation" for Retinoblastoma
1/21/16 K granted FDA Orphan Drug Designation for Pancreatic Cancer
Applying for grants with research partner ?Mayo Clinic?
2/10/16 K approved for Ph2 ovarian cancer trial
2/16/16 K Ph1 trial formally concludes
2/22/16 K Ph1 early data-Increased p21 Expression in 67.5% of Evaluable Patients
3/17/16 P ph2 last patient dosed
5/24, 5/26, 5/31/16 P ph2a successful trial data released (IGA score of 0/1=PASI 90 score)
6/6/16 K ph1 hard lock of data
6/9/16 Rosen/scam lawsuit dismissed by court.
6/15/16 B ph2 ulcerative proctitis 6 week duration overseas trial begins
6/30/16 Arthur P. Bertolino, MD, PhD, MBA, appointed President and CMO
8/30/16 Expansion of Senior Management Team adding Jane Harness,MS, MP
9/16/16 Expansion of Senior Management Team adding LaVonne Lang, DrPH
10/10/16 B ph2 ulcerative colitis/proc (UP), early results 100% and 50% reduction
10/31/16 P ph2b trial begins
1/23/17. B-UP corp update, 2nd cohort prelim observations
2/9/17 K initiation of ph 2 trial , ovarian cancer
2/9/17 K Oral delivery formulation testing commences
2/16/17 Review of expected 2017 clinical milestones
2/22/17 B-UP, ph 2 trial, 3rd cohort commences
2/27/17 CEO update on criminal Rosen/Mako pursuit.
3/3/17 K oral formulation and Leukemia lab studies in Italy updated
3/8/17 B-UP, ph 2 trial, Positive 2nd cohort results released (50%@100% and50%@66%)
3/21/17 B-UP, ph2 expanded favorable data from cohort 2
3/27/17 B-OM Great interim study data. Trial conclusion expected this year.
Conf call ?’s Still focused on being REGN like?
5/18/17 “B- for UP/UPS is well-positioned to become first-in-class.” Ph 2 recruiting complete
5/30/17 K Italy study of AML, Leukemia presenting preclinical findings 6/22-25/17
2
